ActiQs / Forskning

PUBLIKATIONSREGISTRET

Gå till forskningen.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för lotilaner. Visa hela publikationsregistret

En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publikationer i urvalet

33 träffar

Bibliografisk träff 2024-03-21

Efficacy and Safety of Lotilaner Ophthalmic Solution 0.25% for the Treatment of Demodex Blepharitis: A Meta-Analysis of Randomized Controlled Trials.

Muhammad Muneeb Akhtar S, Fareed A, Sohaib Asghar M, Mumtaz M, Kaur S.

Cont Lens Anterior Eye · meta-analysis; systematic review; journal article · DOI 10.1016/j.clae.2024.102148

Bibliografisk träff 2024-03-19

Efficacy and Safety of Lotilaner Ophthalmic Solution (0.25%) for the Treatment of Demodex Blepharitis: A GRADE Assessed Systematic Review and Meta-Analysis of Observational & Experimental Studies.

Talha M, Haris Ali M, Fatima E, Nadeem A, Ahmed A, Nashwan AJ.

Am J Ophthalmol · meta-analysis; systematic review; journal article · DOI 10.1016/j.ajo.2024.03.019

Bibliografisk träff 2024-03-18

XdemvyTM (Lotilaner Ophthalmic Solution) 0.25% Topical Solution for the Treatment of Demodex Blepharitis.

Gupta AK, Mann A, Vincent K, Abramovits W.

Skinmed · journal article

Bibliografisk träff 2024-02-09

Long-Term Outcomes of 6-Week Treatment of Lotilaner Ophthalmic Solution, 0.25%, for Demodex Blepharitis: A Noninterventional Extension Study.

Sadri E, Paauw JD, Ciolino JB, Nijm L, Simmons B, Meyer J, Gaddie IB, Berdy GJ, Holdbrook M, Baba SN, Jalalat P, Yeu E.

Cornea · multicenter study; journal article; observational study · DOI 10.1097/ico.0000000000003484

Bibliografisk träff 2024-02-01

Efficacy and Safety of Lotilaner Ophthalmic Solution 0.25% in the Treatment of Demodex Blepharitis: A Systematic Review and Meta-Analysis.

Abo Zeid M, Elrosasy A, Abbas AW, Elganady A, Rhab AE, Abu Serhan H.

Ocul Immunol Inflamm · meta-analysis; systematic review; journal article · DOI 10.1080/09273948.2024.2309552

Bibliografisk träff 2024-01-21

A Systematic Review and Meta-Analysis of the Safety and Efficacy of 0.25% Lotilaner Ophthalmic Solution in the Treatment of Demodex Blepharitis.

Awan B, Elsaigh M, Tariq A, Badee M, Loomba A, Khedr Y, Abdelmaksoud A.

Cureus · review-article; review; journal article · DOI 10.7759/cureus.52664

Bibliografisk träff 2023-11-01

Lotilaner Ophthalmic Solution 0.25%: First Approval.

Syed YY.

Drugs · review-article; review; journal article · DOI 10.1007/s40265-023-01947-9

Bibliografisk träff 2023-11-01

Correction to: Lotilaner Ophthalmic Solution 0.25%: First Approval.

Syed YY.

Drugs · published erratum; correction · DOI 10.1007/s40265-023-01965-7

Bibliografisk träff 2023-09-25

Canine Systemic Insecticides Fluralaner and Lotilaner Induce Acute Mortality of Triatoma gerstaeckeri, North American Vector of the Chagas Disease Parasite.

Busselman RE, Zecca IB, Hamer GL, Hamer SA.

Am J Trop Med Hyg · research support, non-u.s. gov't; research-article; journal article · DOI 10.4269/ajtmh.23-0300

Bibliografisk träff 2023-06-05

Lotilaner Ophthalmic Solution 0.25% for Demodex Blepharitis: Randomized, Vehicle-Controlled, Multicenter, Phase 3 Trial (Saturn-2).

Gaddie IB, Donnenfeld ED, Karpecki P, Vollmer P, Berdy GJ, Peterson JD, Simmons B, Edell ARP, Whitson WE, Ciolino JB, Baba SN, Holdbrook M, Trevejo J, Meyer J, Yeu E, Saturn-2 Study Group.

Ophthalmology · clinical trial, phase iii; multicenter study; randomized controlled trial; journal article · DOI 10.1016/j.ophtha.2023.05.030

Bibliografisk träff 2023-03-06

Efficacy of lotilaner against myiasis caused by Cochliomyia hominivorax (Diptera: Calliphoridae) in naturally infested dogs.

do Vale TL, Costa AR, Miranda LM, Silva GF, Silva NCS, Lima TB, Chaves DP, Sager H, Lasmar PVF, Costa-Junior LM.

Parasit Vectors · research-article; journal article · DOI 10.1186/s13071-023-05661-z

Bibliografisk träff 2022-08-10

Lotilaner Ophthalmic Solution, 0.25%, for the Treatment of Demodex Blepharitis: Results of a Prospective, Randomized, Vehicle-Controlled, Double-Masked, Pivotal Trial (Saturn-1).

Yeu E, Wirta DL, Karpecki P, Baba SN, Holdbrook M, Saturn I Study Group.

Cornea · research-article; randomized controlled trial; journal article · DOI 10.1097/ico.0000000000003097

Bibliografisk träff 2022-08-01

Treatment of Demodex Blepharitis: A Prospective, Randomized, Controlled, Double-Masked Clinical Trial Comparing Topical Lotilaner Ophthalmic Solution, 0.25% Eyedrops to Vehicle.

Yeu E, Holdbrook M, Baba SN, Ceballos JC, Massaro-Corredor M, Corredor-Ortega C, Ramos-Betancourt N, Quiroz-Mercado H, Gonzalez-Salinas R.

Ocul Immunol Inflamm · randomized controlled trial; journal article · DOI 10.1080/09273948.2022.2093755

Bibliografisk träff 2022-01-21

An assessment of canine ectoparasiticide administration compliance in the USA.

Lavan R, Normile D, Husain I, Singh A, Armstrong R, Heaney K.

Parasit Vectors · research-article; journal article · DOI 10.1186/s13071-021-05134-1

Bibliografisk träff 2021-09-21

Safety and Efficacy of Topical Lotilaner Ophthalmic Solution 0.25% for the Treatment of Demodex Blepharitis: A Pilot Study.

Gonzalez-Salinas R, Yeu E, Holdbrook M, Baba SN, Ceballos JC, Massaro-Corredor M, Corredor-Ortega C, Ramos-Betancourt N, Quiroz-Mercado H.

J Ophthalmol · research-article; journal article · DOI 10.1155/2021/3862684

Bibliografisk träff 2021-07-28

Safety and efficacy of lotilaner ophthalmic solution, 0.25% for the treatment of blepharitis due to demodex infestation: A randomized, controlled, double-masked clinical trial.

Gonzalez-Salinas R, Karpecki P, Yeu E, Holdbrook M, Baba SN, Ceballos JC, Massaro-Corredor M, Corredor-Ortega C, Ramos-Betancourt N, Quiroz-Mercado H.

Cont Lens Anterior Eye · clinical trial, phase ii; randomized controlled trial; journal article · DOI 10.1016/j.clae.2021.101492

Bibliografisk träff 2021-06-13

Early onset of pre-lethal effects of lotilaner (Credelio®) on Amblyomma americanum ticks on experimentally infested dogs.

Wenger MJ, Kollasch TM, Burke MC, Jones L, Locklear C, Hedberg M, Miller L, Reeves S, Ritchie D, Rumschlag AJ, Ryan WG, Smith V, Sutherland C, Reif KE, Herrin BH.

Parasit Vectors · research-article; journal article · DOI 10.1186/s13071-021-04817-z

Bibliografisk träff 2021-06-04

Field study to investigate the effectiveness and safety of a novel orally administered combination drug product containing milbemycin oxime and lotilaner (Credelio® Plus) against natural flea and tick infestations on dogs presented as veterinary patients in Europe.

Forster S, Wiseman S, Snyder DE.

Parasit Vectors · research-article; multicenter study; journal article; clinical trial, veterinary · DOI 10.1186/s13071-021-04808-0

Bibliografisk träff 2021-05-28

Long-term and acute safety of a novel orally administered combination drug product containing milbemycin oxime and lotilaner (Credelio® Plus) in juvenile and adult dogs.

Riggs KL, Wiseman S.

Parasit Vectors · randomized controlled trial, veterinary; research-article; journal article · DOI 10.1186/s13071-021-04760-z

Bibliografisk träff 2021-05-28

Field study to investigate the effectiveness and safety of a novel orally administered combination drug product containing milbemycin oxime and lotilaner (Credelio® Plus) for the prevention of heartworm disease (Dirofilaria immitis) in client-owned dogs in the USA.

Young LM, Wiseman S, Crawley E, Wallace K, Snyder DE.

Parasit Vectors · randomized controlled trial, veterinary; research-article; journal article · DOI 10.1186/s13071-021-04767-6

Bibliografisk träff 2021-05-28

Credelio® Plus: a novel oral endectocide for dogs.

Traversa D.

Parasit Vectors · comment; letter; journal article · DOI 10.1186/s13071-021-04774-7

Bibliografisk träff 2021-05-17

Effectiveness of a novel orally administered combination drug product containing milbemycin oxime and lotilaner (Credelio® Plus) for the treatment of larval and immature adult stages of Ancylostoma caninum in experimentally infected dogs.

Snyder DE, Wiseman S, Crawley E, Wallace K, Bowman DD, Reinemeyer CR.

Parasit Vectors · research-article; journal article · DOI 10.1186/s13071-021-04761-y

Bibliografisk träff 2021-05-17

Field study to investigate the effectiveness and safety of a novel orally administered combination drug product containing milbemycin oxime and lotilaner (Credelio® Plus) against natural intestinal nematode infections in dogs presented as veterinary patients in Europe.

Hayes B, Wiseman S, Snyder DE.

Parasit Vectors · research-article; multicenter study; journal article · DOI 10.1186/s13071-021-04766-7

Bibliografisk träff 2021-05-17

Effectiveness of Credelio® Plus, a novel chewable tablet containing milbemycin oxime and lotilaner for the treatment of larval and immature adult stages of Toxocara canis in experimentally infected dogs.

Young LM, Wiseman S, Crawley E, Bowman DD, Reinemeyer CR, Snyder DE.

Parasit Vectors · research-article; journal article · DOI 10.1186/s13071-021-04762-x

Bibliografisk träff 2021-03-05

Efficacy of lotilaner (Credelio™) against experimentally induced infestations of the adult cat flea, Ctenocephalides felis, and flea eggs following oral administration to cats.

Paarlberg T, Karadzovska D, Helbig R.

Parasit Vectors · research-article; journal article · DOI 10.1186/s13071-021-04660-2

Bibliografisk träff 2021-03-01

A randomized, controlled field study to assess the efficacy and safety of lotilaner flavored chewable tablets (Credelio™ CAT) in eliminating fleas in client-owned cats in the USA.

Chappell K, Paarlberg T, Seewald W, Karadzovska D, Nanchen S.

Parasit Vectors · randomized controlled trial, veterinary; research-article; journal article · DOI 10.1186/s13071-021-04617-5

Bibliografisk träff 2020-01-14

Efficacy of lotilaner (Credelio™) against the adult cat flea, Ctenocephalides felis and flea eggs following oral administration to dogs.

Young L, Karadzovska D, Wiseman S, Helbig R.

Parasit Vectors · randomized controlled trial, veterinary; research-article; journal article · DOI 10.1186/s13071-019-3873-1

Bibliografisk träff 2019-04-04

In-home assessment of flea control and dermatologic lesions in dogs provided by lotilaner (Credelio®) and spinosad (Comfortis®) in west central Florida.

Dryden MW, Canfield MS, Herrin BH, Bocon C, Bress TS, Hickert A, Kollasch TM, Phan L, Rumschlag AJ, Ryan WG, Sampeck B, Smith N, Smith V, Warcholek SA.

Vet Parasitol X · research-article; journal article · DOI 10.1016/j.vpoa.2019.100009

Bibliografisk träff 2019-04-04

In-home assessment of flea control and dermatologic lesions in dogs provided by lotilaner (Credelio®) and spinosad (Comfortis®) in west central Florida.

Dryden MW, Canfield MS, Herrin BH, Bocon C, Bress TS, Hickert A, Kollasch TM, Phan L, Rumschlag AJ, Ryan WG, Sampeck B, Smith N, Smith V, Warcholek SA.

Vet Parasitol · journal article · DOI 10.1016/j.vpoa.2019.100009

Bibliografisk träff 2018-08-02

Laboratory evaluation of the efficacy of lotilaner (Credelio™) against Haemaphysalis longicornis infestations of dogs.

Otaki H, Sonobe J, Murphy M, Cavalleri D, Seewald W, Drake J, Nanchen S.

Parasit Vectors · research-article; journal article · DOI 10.1186/s13071-018-3032-0

Gå till forskningen.

Publikationer i urvalet

Efficacy and Safety of Lotilaner Ophthalmic Solution 0.25% for the Treatment of Demodex Blepharitis: A Meta-Analysis of Randomized Controlled Trials.

Efficacy and Safety of Lotilaner Ophthalmic Solution (0.25%) for the Treatment of Demodex Blepharitis: A GRADE Assessed Systematic Review and Meta-Analysis of Observational & Experimental Studies.

Xdemvy<sup>TM</sup> (Lotilaner Ophthalmic Solution) 0.25% Topical Solution for the Treatment of <i>Demodex</i> Blepharitis.

Long-Term Outcomes of 6-Week Treatment of Lotilaner Ophthalmic Solution, 0.25%, for Demodex Blepharitis: A Noninterventional Extension Study.

Efficacy and Safety of Lotilaner Ophthalmic Solution 0.25% in the Treatment of Demodex Blepharitis: A Systematic Review and Meta-Analysis.

A Systematic Review and Meta-Analysis of the Safety and Efficacy of 0.25% Lotilaner Ophthalmic Solution in the Treatment of Demodex Blepharitis.

Lotilaner Ophthalmic Solution 0.25%: First Approval.

Correction to: Lotilaner Ophthalmic Solution 0.25%: First Approval.

Canine Systemic Insecticides Fluralaner and Lotilaner Induce Acute Mortality of Triatoma gerstaeckeri, North American Vector of the Chagas Disease Parasite.

Lotilaner Ophthalmic Solution 0.25% for Demodex Blepharitis: Randomized, Vehicle-Controlled, Multicenter, Phase 3 Trial (Saturn-2).

Efficacy of lotilaner against myiasis caused by Cochliomyia hominivorax (Diptera: Calliphoridae) in naturally infested dogs.

Lotilaner Ophthalmic Solution, 0.25%, for the Treatment of Demodex Blepharitis: Results of a Prospective, Randomized, Vehicle-Controlled, Double-Masked, Pivotal Trial (Saturn-1).

Treatment of <i>Demodex</i> Blepharitis: A Prospective, Randomized, Controlled, Double-Masked Clinical Trial Comparing Topical Lotilaner Ophthalmic Solution, 0.25% Eyedrops to Vehicle.

An assessment of canine ectoparasiticide administration compliance in the USA.

Safety and Efficacy of Topical Lotilaner Ophthalmic Solution 0.25% for the Treatment of <i>Demodex</i> Blepharitis: A Pilot Study.

Safety and efficacy of lotilaner ophthalmic solution, 0.25% for the treatment of blepharitis due to demodex infestation: A randomized, controlled, double-masked clinical trial.

Early onset of pre-lethal effects of lotilaner (Credelio<sup>®</sup>) on Amblyomma americanum ticks on experimentally infested dogs.

Field study to investigate the effectiveness and safety of a novel orally administered combination drug product containing milbemycin oxime and lotilaner (Credelio<sup>®</sup> Plus) against natural flea and tick infestations on dogs presented as veterinary patients in Europe.

Long-term and acute safety of a novel orally administered combination drug product containing milbemycin oxime and lotilaner (Credelio<sup>®</sup> Plus) in juvenile and adult dogs.

Field study to investigate the effectiveness and safety of a novel orally administered combination drug product containing milbemycin oxime and lotilaner (Credelio<sup>®</sup> Plus) for the prevention of heartworm disease (Dirofilaria immitis) in client-owned dogs in the USA.

Credelio® Plus: a novel oral endectocide for dogs.

Effectiveness of a novel orally administered combination drug product containing milbemycin oxime and lotilaner (Credelio<sup>®</sup> Plus) for the treatment of larval and immature adult stages of Ancylostoma caninum in experimentally infected dogs.

Field study to investigate the effectiveness and safety of a novel orally administered combination drug product containing milbemycin oxime and lotilaner (Credelio<sup>®</sup> Plus) against natural intestinal nematode infections in dogs presented as veterinary patients in Europe.

Effectiveness of Credelio<sup>®</sup> Plus, a novel chewable tablet containing milbemycin oxime and lotilaner for the treatment of larval and immature adult stages of Toxocara canis in experimentally infected dogs.

Efficacy of lotilaner (Credelio™) against experimentally induced infestations of the adult cat flea, Ctenocephalides felis, and flea eggs following oral administration to cats.

A randomized, controlled field study to assess the efficacy and safety of lotilaner flavored chewable tablets (Credelio™ CAT) in eliminating fleas in client-owned cats in the USA.

Efficacy of lotilaner (Credelio™) against the adult cat flea, Ctenocephalides felis and flea eggs following oral administration to dogs.

In-home assessment of flea control and dermatologic lesions in dogs provided by lotilaner (Credelio<sup>®</sup>) and spinosad (Comfortis<sup>®</sup>) in west central Florida.

In-home assessment of flea control and dermatologic lesions in dogs provided by lotilaner (Credelio®) and spinosad (Comfortis®) in west central Florida.

Laboratory evaluation of the efficacy of lotilaner (Credelio™) against Haemaphysalis longicornis infestations of dogs.